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Introduction: This report describes the challenges of treating a pregnant woman who had a rare case of critical
placenta accreta with concurrent Cromer system anti-Tc(a) and anti-Kidd A alloantibodies. No previous case of such
alloimmunization in a patient with placenta accreta has been reported.
Case presentation: A 28-year-old African woman with anti-Cromer Tc(a) antibodies, anti-Kidd A antibodies and
placenta accreta was admitted to the obstetric emergency department at our university hospital with persistent
vaginal bleeding. Her rare Cromer blood group system antibodies had been diagnosed 1 month earlier; no compatible
blood had been found despite a worldwide search. We performed a cesarean section after placement of Fogarty
balloons in her uterine arteries with preoperative endovascular interventional radiology. Other therapeutic interventions
included preoperative iron administration to raise hemoglobin and the scheduled predeposit of autologous blood.
Intraoperative therapeutic management was aimed at preventing coagulopathy and massive bleeding. With the use of
alternative medical techniques determined during perioperative planning, her intraoperative blood loss was only
1000mL, despite the placenta accreta. She was discharged from the hospital 4 days after cesarean section.
Conclusions: To the best of our knowledge, this is the first report of an alloimmunized patient with two different
alloantibodies and concurrent high risk of bleeding because of placenta accreta. The close collaboration among
obstetricians, anesthesiologists, interventional radiologists, blood bank pathologists and intensive care doctors
prevented serious consequences in this patient. The exceptional feature of this case is the patient’s double risk: the
placenta accreta and the inability to transfuse compatible blood. These two extreme situations challenged the
multidisciplinary medical team.
Keywords: Cromer blood group system antibodies, Endovascular intervention, Intensive care unit, Peripartum
hemorrhage, Placenta accretaIntroduction
The Italian National Institute of Health recently con-
ducted a study to analyze causes of maternal death and
to compute maternal mortality ratios in six regions of
Italy, including our region. The total maternal mortality
ratio was 11.8/100,000 live births, with hemorrhage and
hypertensive disorders the greatest risk factors for obstet-
ric death [1]. The management of pregnant women with a* Correspondence: stefanobusani7@gmail.com
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requiring the cooperation of a multidisciplinary medical
team. Clinicians should engage in a detailed discussion to
anticipate possible complications during childbirth, and to
define the optimal time of delivery, location of procedures,
sequence of events, transfusion requirements, type of
anesthesia and postoperative care [2-4].
Patients with abnormal placental insertion, including
placenta accreta, increta and percreta, have a high risk
of hemorrhage. These conditions are characterized by
abnormally tight adhesion between placenta and uterus,
which can result in massive hemorrhage during deliveryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the presence of rare antibodies against the Cromer blood
group system, the risk of death during delivery becomes
exponentially higher [6-8].
We report the first case of a pregnant woman with
critical placenta accreta and concurrent Cromer anti-
Tc(a) antibodies and anti-Kidd A (JKa) antibodies.
Because of her high risk of hemorrhage and the extreme
difficulty of finding compatible blood, the patient had a
cesarean delivery with the intraoperative support of a
multidisciplinary team.
Case presentation
A 28-year-old African woman (72kg, 166cm) with anti-
Cromer Tc(a) and anti-Jka antibodies was admitted to
the obstetric emergency department at our University
Hospital at 31+4 weeks’ gestation for heavy vaginal
bleeding. She had a history of two prior at-term cesarean
deliveries (in 2006 and 2010) and two voluntary abor-
tions. She had a positive indirect Coombs test near the
beginning of pregnancy. Low-titer anti-Tc(a) antibodies
had been identified and closely monitored.
A month before admission to our department (at 27+3
weeks’ gestation), she had been hospitalized for cervical
shortening (23mm). Ultrasonography at that time had
revealed full placenta previa and a high risk for placenta
accreta. In accordance with the guidelines of the Royal
College of Obstetricians and Gynaecologists [9], the ultra-
sound report was as follows: “… in grey-scale, a thinning
of the hyperechoic serosa–bladder interface and abnormal
placental lacunae were found. Moreover, the placental
tissue on the left side of the uterus appeared to reach the
serosa.” During the initial hospitalization, two injections of
betamethasone (12mg) were administered to prevent
fetal respiratory distress, and a consulting hematologist
requested further immunohematological testing.
Because of the rarity of antibodies of the Cromer
blood group system and the high risk of heavy bleeding
associated with placenta accreta, it was necessary to
establish specific policies for the planned delivery by
cesarean section. In preparation, parenteral iron supple-
mentation was administered twice weekly beginning in
the 28th week to raise hemoglobin (Hb) values above
12g/dL from an initial Hb of 10.5g/dL. Meanwhile, the
Transfusion Medicine Department consultant planned
two autologous blood donations because no compatible
blood was found in a search of the United States Blood
Bank network or the network of European blood banks
(World Health Organization International Rare Donor
Panel). Unfortunately, the autologous blood could not be
collected because of sudden worsening of the patient’s
clinical condition.
At her readmission to our Obstetrical Emergency Depart-
ment, serial ultrasound examinations and fetal monitoringwith cardiotocography were performed. Because vaginal
bleeding stopped within a few hours in response to
tocolytic therapy, the attending physicians decided to
maintain a conservative strategy. Elective cesarean delivery
was scheduled with multidisciplinary team cooperation
because of the extreme complexity of the case. The
cesarean section was performed 3 days later, after a long
and detailed discussion among anesthesiologists, obstetri-
cians, radiologists, hematologists and intensivists. Her pre-
operative Hb was 10.2g/dL.
Before cesarean section, the patient provided written
informed consent and was brought to the angiography
suite (Philips Medical Systems, Best, Netherlands). We
placed two 14-gauge and one 16-gauge peripheral ven-
ous catheters and performed radial artery cannulation to
monitor intra-arterial pressure throughout the proce-
dures. After local anesthesia of her groin bilaterally, her
femoral arteries were punctured with Seldinger tech-
nique and 4-Fr sheaths (Terumo, Leuven, Belgium) were
placed to allow bilateral cross catheterization of her
hypogastric arteries with a C1 “Cobra” catheter (Terumo
Leuven, Belgium). Using a 0.035 inch 150cm Amplatz
guidewire (Cordis, Fremont, CA, USA), the 4-Fr sheaths
were exchanged with two 45cm 5-Fr Brite Tip® sheaths
(Cordis, Fremont, CA, USA), with the distal tips in the
anterior branches of both hypogastric arteries. This
allowed placement of two Fogarty 80cm 4-Fr balloons
over the distal tips of the 5-Fr sheaths, within her uter-
ine arteries. Proper positioning of the Fogarty balloons
and the effectiveness of vascular occlusion were con-
firmed with fluoroscopy (Figure 1). Maternal and fetal
monitoring were conducted throughout the procedure,
without complications.
She was transferred from the angiography suite to the
obstetric operating room. A single fluoroscopic image
was made with a moveable C-arm to confirm that the
Fogarty balloons remained in the proper position. While
she underwent the angiographic procedure, the operat-
ing room was set up with an intraoperative blood salvage
system (Cell Saver®; Haemonetics Corp., Braintree, MA,
USA), a rapid infusion system (Haemonetics Corp.,
Braintree, MA, USA), fluid warmers (Level 1 H-1200;
Smiths Medical, Kent, UK) and forced air warming
systems (Bair-Hugger™, 3M, St. Paul, MN, USA). Before
anesthetic induction, she received premedication with
hydrocortisone (200mg) as recommended by the
hematologist in case of emergent need to transfuse incom-
patible blood. She also received antibiotic prophylaxis and
intravenous tranexamic acid (750mg) to prevent peripar-
tum hemorrhage [10]. Anesthesia was induced with
200mg propofol, 200mcg fentanyl and 40mg rocuronium
and was maintained with sevoflurane gas. A low trans-
verse skin incision through her previous cesarean scars
and a lower uterine segment incision were performed,
Figure 1 The two Fogarty balloons, over the distal tips of the 5 Fr sheaths, inside the uterine arteries. Both balloons were inflated for the
confirmation of the effectiveness of the stop flow through fluoroscopic image.
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diately after delivery of the fetus and umbilical cord
clamping, the uterine artery balloons were inflated. As per
the obstetrician’s request, the uterine arteries were embo-
lized with Gelfoam® sponge (Jinling Pharmaceutical
Company, Nanjing, China) to stop bleeding. Because the
placenta could not be completely removed as a result of
its strong adhesion to the posterior wall of the uterus, and
because of the risk of postoperative hemorrhage, the
surgeons decided to perform a total hysterectomy, as
recommended by Royal College of Obstetricians and
Gynaecologists guidelines [9]. When adequate hemostatic
control was achieved, the balloons were deflated. After the
uterine lumen and abdominal cavity were closed and no
vaginal bleeding was confirmed, the Fogarty balloons were
removed. The 5-Fr sheaths were maintained for 24 hours
in case further embolization was necessary. The total in-
traoperative blood loss was 1000mL and the surgery lasted
approximately 150 minutes. During the cesarean section,
150mL of blood was reinfused through the cell salvage
technology and limited crystalloid fluid therapy was
administered (1L of lactated Ringer’s solution). Her
temperature was maintained at approximately 37°C
throughout the procedure and serial blood gas ana-
lyses were performed to monitor for metabolic acid-
osis and electrolyte abnormalities. Further details of
our hemorrhage management protocol have been
reported previously [11].
After surgery, she was admitted to our Intensive Care
Unit (ICU) for close monitoring of bleeding and coagu-
lation profiles. Immediately after ICU admission,ventilation was optimized, adequate analgesia was pro-
vided and she was awakened and extubated. Because no
further bleeding was recorded from the abdominal drain,
the angiographic 5-Fr sheaths were removed the day
after surgery and she was transferred to the obstetric
ward with a Hb of 8.9g/dL.
Four days after cesarean section, she was discharged
from our hospital with a prescription for oral iron ther-
apy for at least 30 days and plans for blood count
recheck 15 days after discharge.
Discussion
The presence of antibodies against the Cromer blood
group system is a rare hematologic condition, reported
only a few times, and thus this condition is probably
underdiagnosed [6-8]. Diagnosis is important because
appropriate hematologic, anesthetic, radiologic and
intensive care support is necessary in case of surgery for
individuals with this condition. Individuals (only nine
identified by the World Health Organization International
Rare Donor Panel to date) negative for all Cromer anti-
gens (null phenotype) lack the decay-accelerating factor
(DAF) on their red blood cells (RBC) but do not have an
increased susceptibility to hemolysis during normal activ-
ities of daily living [8]. The antigens (12 high- and three
low-prevalence) of the Cromer blood group system are
carried on DAF, which is a member of the family of com-
plement activation regulators. One function of DAF is to
protect cells from autologous complement attack [12].
DAF is expressed on RBC, white blood cells, platelets and
epithelial tissues, and on the apical surface of placental
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This suggests that DAF may play a strategic role in
protecting the antigenically foreign fetus from maternal
complement attack, thus performing an important role in
the maintenance of human pregnancy [8]. Antibodies with
specificity to the Cromer system antigens, anti-Tc(a), can
cause post-transfusion severe hemolytic reactions [6,7].
Pregnancy is definitely a risk for Cromer-sensitized
patients and can be life-threatening if associated with
obstetric anomalies that predispose to massive hemorrhage.
Several medical professionals were included in the
long discussion that was held before the cesarean
section, focusing on a series of questions. Every possible
strategy to prevent massive bleeding was debated at
length. It was agreed that endovascular intervention with
temporary balloons was necessary and that hysterectomy
would be performed if critical bleeding occurred. Despite
the lack of strong evidence for its use [13], some centers
have established protocols for interventional radiology to
reduce blood loss in cases of placenta accreta. We
decided to pursue this strategy, based on the experience
of our interventional radiologists. Although hysterec-
tomy is recommended only in case of massive bleeding,
the procedure was performed in this case to prevent
possible further postoperative bleeding.
Another critical point that we needed to address was
the patient’s intraoperative management, including moni-
toring, fluids, procoagulant drugs and type of anesthesia.
We decided to perform general anesthesia with the intra-
operative use of cell salvage technology, despite the
strongly debated risk of amniotic fluid embolism [14].
Because we had no other option for transfusing this
patient, we decided to assume this risk; fortunately amni-
otic fluid embolism did not occur. During the cesarean
section, the coagulation system was the focus of attention
to avoid triggering coagulopathy; the patient’s temperature,
acid-base balance and electrolytes were closely monitored
and readily corrected. The most salient point in the long
discussion among anesthesiologists and blood bank pathol-
ogists was the Hb cut-off for transfusion with incompatible
blood. In the end, we decided to risk transfusing the patient
if her Hb fell below 6g/dL. We were well aware of the risk
of poor tissue perfusion if the cut-off was too low, and of
severe hemolytic syndrome if the cut-off was too high.
Conclusions
The exceptional feature of this case was the double risk
to which this pregnant patient was subjected rather than
the treatment she received. The presence of placenta
accreta with no availability of compatible blood for
transfusion challenged the multidisciplinary team. The
close collaboration among obstetricians, anesthesiologists,
interventional radiologists, blood bank pathologists and
intensive care doctors prevented serious consequences inthis patient. We believe that this case provides interest-
ing ideas that may aid clinicians in treating patients
with exceptional risk of bleeding and the inability to
transfuse compatible blood as a result of alloimmuniza-
tion. We believe that the choices we had to make will
provide food for thought for those handling similar
situations in the future.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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